Profile data is unavailable for this security.
About the company
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
- Revenue in INR (TTM)16.94bn
- Net income in INR4.57bn
- Incorporated1990
- Employees777.00
- LocationCaplin Point Laboratories LtdNarbaviNo. 3, Lakshmanan Street,, T. Nagar,CHENNAI 600096IndiaIND
- Phone+91 4 428156653
- Fax+91 4 428154952
- Websitehttps://www.caplinpoint.net/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Ltd | 8.19bn | 915.95m | 48.67bn | 838.00 | 50.13 | 4.16 | 38.10 | 5.94 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 49.09bn | 1.40k | 22.63 | 2.79 | 16.92 | 2.65 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 62.00bn | -- | 37.84 | 7.33 | 32.32 | 8.71 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 64.12bn | 1.40k | 20.42 | 3.11 | 16.48 | 2.94 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 66.01bn | 407.00 | -- | 52.49 | -- | 87.37 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
| F D C Ltd | 19.43bn | 3.05bn | 68.96bn | 6.37k | 22.76 | 3.29 | 19.99 | 3.55 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 77.02bn | 2.85k | -- | 3.62 | 106.75 | 1.90 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 77.57bn | 1.57k | 25.85 | 6.05 | 21.56 | 4.98 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Wockhardt Ltd | 27.98bn | -4.63bn | 78.85bn | 2.74k | -- | 2.36 | -- | 2.82 | -32.04 | -32.04 | 193.86 | 218.12 | 0.365 | 1.80 | 3.95 | -- | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.79 | -16.87 | -12.70 | 0.5532 | -0.1906 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 79.61bn | 1.41k | 37.22 | -- | 33.07 | 6.81 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 94.20bn | 777.00 | 20.71 | 4.07 | 18.30 | 5.56 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Granules India Ltd | 45.06bn | 4.05bn | 99.86bn | 3.65k | 24.63 | 3.10 | 16.30 | 2.22 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 101.20bn | 1.82k | 21.52 | 4.34 | 19.30 | 4.43 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 67.03bn | 771.00m | 101.49bn | 1.03k | 132.15 | 1.87 | 22.33 | 1.51 | 4.85 | 4.85 | 421.25 | 343.16 | 0.5904 | 1.60 | 7.14 | -- | 0.6404 | 2.96 | 0.7627 | 3.55 | 68.06 | 69.37 | 1.08 | 5.13 | 1.37 | 2.09 | 0.4033 | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 123.87bn | 3.55k | 31.63 | 4.79 | 21.37 | 6.17 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 141.00bn | 947.00 | 87.30 | 19.80 | 79.91 | 10.88 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
Data as of Jun 07 2024. Currency figures normalised to Caplin Point Laboratories Ltd's reporting currency: Indian Rupee INR
2.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 May 2024 | 919.59k | 1.21% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 353.72k | 0.47% |
| Principal Global Investors LLCas of 30 Apr 2024 | 240.08k | 0.32% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 145.45k | 0.19% |
| PineBridge Investments Asia Ltd.as of 31 Dec 2023 | 87.75k | 0.12% |
| BlackRock Fund Advisorsas of 09 May 2024 | 51.52k | 0.07% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 42.45k | 0.06% |
| The Vanguard Group, Inc.as of 30 Apr 2024 | 35.67k | 0.05% |
| TIAA-CREF Investment Management LLCas of 30 Apr 2024 | 18.19k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 17.38k | 0.02% |
More ▼
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
